Also known as: AChR
TG Therapeutics reported positive Phase 1 data for subcutaneous BRIUMVI in myasthenia gravis and started a Phase 2 trial; five-year ULTIMATE data in JAMA Neurology showed sustained MS efficacy.
The FDA expanded efgartigimod approval to all adult generalized myasthenia gravis serotypes. Phase 3 ADAPT SERON met its primary endpoint and showed no new safety signals.
Amgen received FDA and European Commission approval for Uplizna to treat generalized myasthenia gravis in adults who are anti-AChR or anti-MuSK antibody positive, offering twice-yearly maintenance dosing after initial loading doses.
